Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?

Harrison MR.

Clin Med Insights Oncol. 2011;5:349-64. doi: 10.4137/CMO.S6087. Epub 2011 Nov 7.

2.

The prospects of pazopanib in advanced renal cell carcinoma.

Gupta S, Spiess PE.

Ther Adv Urol. 2013 Oct;5(5):223-32. doi: 10.1177/1756287213495099.

3.

Targeted Therapy for Metastatic Renal Cell Carcinoma.

Afriansyah A, Hamid AR, Mochtar CA, Umbas R.

Acta Med Indones. 2016 Oct;48(4):335-347. Review.

4.

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma.

Bukowski RM.

Cancer Manag Res. 2011;3:273-85. doi: 10.2147/CMR.S15557. Epub 2011 Aug 10.

5.

Optimal management of metastatic renal cell carcinoma: current status.

Escudier B, Albiges L, Sonpavde G.

Drugs. 2013 Apr;73(5):427-38. doi: 10.1007/s40265-013-0043-1. Review.

PMID:
23572408
6.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
7.

Pazopanib for the treatment of patients with advanced renal cell carcinoma.

Lang JM, Harrison MR.

Clin Med Insights Oncol. 2010 Oct 1;4:95-105. doi: 10.4137/CMO.S4088.

8.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
9.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
10.

Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.

Miller LA, Stemkowski S, Saverno K, Lane DC, Tao Z, Hackshaw MD, Loy B.

J Manag Care Spec Pharm. 2016 Mar;22(3):219-26. doi: 10.18553/jmcp.2016.22.3.219.

11.

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M.

Med Oncol. 2012 Sep;29(3):1896-907. doi: 10.1007/s12032-011-0016-8. Epub 2011 Jul 7. Review.

PMID:
21735145
12.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.

PMID:
24795159
13.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
14.

Current management of metastatic renal cell carcinoma: evolving new therapies.

Kumar R, Kapoor A.

Curr Opin Support Palliat Care. 2017 Jun 5. doi: 10.1097/SPC.0000000000000277. [Epub ahead of print]

PMID:
28590313
15.

Sunitinib malate for the treatment of renal cell carcinoma.

Wood L.

Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Review.

PMID:
22607009
16.

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Pal SK, Figlin RA.

Target Oncol. 2011 Mar;6(1):5-16. doi: 10.1007/s11523-011-0172-y. Epub 2011 Apr 12. Review.

17.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

18.

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.

Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10. Review.

PMID:
27664394
19.

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

Pal SK, Figlin RA.

Clin Med Insights Oncol. 2010 Jun 9;4:43-53.

20.

[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].

Miller K, Bergmann L, Doehn C, Gschwend J, Keilholz U.

Aktuelle Urol. 2017 Feb;48(1):72-78. doi: 10.1055/s-0042-117572. Epub 2017 Apr 12. German.

PMID:
28403496

Supplemental Content

Support Center